TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: Arm Label: Enoxaparin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Enoxaparin | Arm Label: Fondaparinux; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fondaparinux | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin | Intervention Type: DRUG; Name: Fondaparinux; Assigned to Arm(s): Fondaparinux
B: Arm Label: Enoxaparin; Type: EXPERIMENTAL; Interventions: Drug: Enoxaparin | Arm Label: Current standard of care (no enoxaparin); Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Enoxaparin; Assigned to Arm(s): Enoxaparin
C: Arm Label: I; Type: EXPERIMENTAL; Interventions: Procedure: catheter-directed venous thrombolysis | Arm Label: II; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: catheter-directed venous thrombolysis; Assigned to Arm(s): I
D: Arm Label: Apixaban 2.5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban 2.5 MG | Arm Label: Apixaban 5mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Apixaban 5MG | Arm Label: Aspirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aspirin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Apixaban 2.5 MG; Assigned to Arm(s): Apixaban 2.5mg | Intervention Type: DRUG; Name: Apixaban 5MG; Assigned to Arm(s): Apixaban 5mg | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): Aspirin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: Arm Label: I; Type: EXPERIMENTAL; Interventions: Procedure: catheter-directed venous thrombolysis | Arm Label: II; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: catheter-directed venous thrombolysis; Assigned to Arm(s): I
B: Intervention Type: DEVICE; Name: Elastic stockings; Assigned to Arm(s): N/A
C: Arm Label: Active ECS; Type: ACTIVE_COMPARATOR; Interventions: Device: Knee-length, graduated elastic compression stocking | Arm Label: Placebo ECS; Type: PLACEBO_COMPARATOR; Interventions: Device: Knee-length, placebo stocking | Intervention Type: DEVICE; Name: Knee-length, graduated elastic compression stocking; Assigned to Arm(s): Active ECS | Intervention Type: DEVICE; Name: Knee-length, placebo stocking; Assigned to Arm(s): Placebo ECS
D: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Catheter-directed Venous Thrombolysis in Acute Iliofemoral Vein Thrombosis, an Open Randomized, Controlled, Clinical Trial
Brief Summary: Deep vein thrombosis (DVT) is a severe disease, and conventional treatment with low molecular weight heparin (LMWH) and warfarin is associated with some degree of long-term sequelae, i.e. post-thrombotic syndrome (PTS). Catheter-directed thrombolytic (CDT) therapy has been introduced worldwide the last two decades. Reports have suggested a beneficial effect of this costly treatment, but there are no randomized clinical trials documenting its short- and long-term efficacy and safety. This multi-center study will randomize patients with acute iliofemoral vein thrombosis to either conventional treatment or CDT in addition to conventional treatment. Main outcome parameters are patency rates at 6 months and prevalence of PTS at 24 months. The main short-term hypothesis is that CDT of first-time acute DVT will increase patency of the affected segments after 6 months from \<50% to \>80%. The main long-term hypothesis is that CDT will improve long-term functional outcome, i.e. risk of PTS after 2 years from \>25% to \<10%.


Options:
A: Arm Label: Conventional anticoagulation therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Ekos Endowave system thrombolysis; Type: EXPERIMENTAL; Interventions: Device: Ekos endowave system thrombolysis | Intervention Type: DEVICE; Name: Ekos endowave system thrombolysis; Assigned to Arm(s): Ekos Endowave system thrombolysis
B: Arm Label: A-Intervention; Type: EXPERIMENTAL; Interventions: Drug: Recombinant tissue plasminogen activator (rt-PA) | Arm Label: B-Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Recombinant tissue plasminogen activator (rt-PA); Assigned to Arm(s): A-Intervention
C: Arm Label: CDT+US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT+US group | Arm Label: CDT-US group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: CDT-US group | Intervention Type: PROCEDURE; Name: CDT+US group; Assigned to Arm(s): CDT+US group | Intervention Type: PROCEDURE; Name: CDT-US group; Assigned to Arm(s): CDT-US group
D: Arm Label: I; Type: EXPERIMENTAL; Interventions: Procedure: catheter-directed venous thrombolysis | Arm Label: II; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: catheter-directed venous thrombolysis; Assigned to Arm(s): I

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Decision-Making for Colorectal Cancer Screening
Brief Summary: The overall objective of this study is to conduct a three-arm randomized controlled trial to evaluate the impact of an interactive, web-based decision aid on shared decision-making and patient adherence to colorectal cancer (CRC) screening recommendations.


Options:
A: Arm Label: Decision aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Decision Aid | Arm Label: Normal care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Decision Aid; Assigned to Arm(s): Decision aid
B: Arm Label: Decision aid plus YourDiseaseRisk; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based decision aid plus personalized risk assessment | Arm Label: Decision aid alone; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based decision aid alone | Arm Label: III; Type: SHAM_COMPARATOR; Interventions: Behavioral: Generic website | Intervention Type: BEHAVIORAL; Name: Web-based decision aid plus personalized risk assessment; Assigned to Arm(s): Decision aid plus YourDiseaseRisk | Intervention Type: BEHAVIORAL; Name: Web-based decision aid alone; Assigned to Arm(s): Decision aid alone | Intervention Type: BEHAVIORAL; Name: Generic website; Assigned to Arm(s): III
C: Arm Label: Solo Learning; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Skin Self Examination Information and ABCDE Rule | Arm Label: Dyadic Learning; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Skin Self Examination Information and ABCDE Rule | Intervention Type: BEHAVIORAL; Name: Skin Self Examination Information and ABCDE Rule; Assigned to Arm(s): Dyadic Learning, Solo Learning
D: Arm Label: shared decision making; Type: EXPERIMENTAL; Interventions: Behavioral: Shared decision making | Arm Label: control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared decision making; Assigned to Arm(s): shared decision making

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Decision-Making for Colorectal Cancer Screening
Brief Summary: The overall objective of this study is to conduct a three-arm randomized controlled trial to evaluate the impact of an interactive, web-based decision aid on shared decision-making and patient adherence to colorectal cancer (CRC) screening recommendations.


Options:
A: Arm Label: Using Power Up; Type: EXPERIMENTAL; Interventions: Behavioral: Shared Decision Making tool | Arm Label: Not using Power Up; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Shared Decision Making tool; Assigned to Arm(s): Using Power Up
B: Arm Label: White educational video; Type: N/A; Interventions: N/A | Arm Label: African-American educational video; Type: N/A; Interventions: N/A | Arm Label: Usual care; Type: N/A; Interventions: N/A
C: Arm Label: Decision aid plus YourDiseaseRisk; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based decision aid plus personalized risk assessment | Arm Label: Decision aid alone; Type: EXPERIMENTAL; Interventions: Behavioral: Web-based decision aid alone | Arm Label: III; Type: SHAM_COMPARATOR; Interventions: Behavioral: Generic website | Intervention Type: BEHAVIORAL; Name: Web-based decision aid plus personalized risk assessment; Assigned to Arm(s): Decision aid plus YourDiseaseRisk | Intervention Type: BEHAVIORAL; Name: Web-based decision aid alone; Assigned to Arm(s): Decision aid alone | Intervention Type: BEHAVIORAL; Name: Generic website; Assigned to Arm(s): III
D: Arm Label: Patient decision aids; Type: EXPERIMENTAL; Interventions: Other: Patient decision aid | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Patient decision aid; Assigned to Arm(s): Patient decision aids

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Online Health Records for Patient Safety and Care
Brief Summary: The study uses a randomized, prospective cohort design to assess the impact of shared online health records on 1) patient safety, 2) health goal adherence and outcomes, 3) documentation of family history, and 4) barriers to the adoption of patient-physician communication technology.

Hypothesis: the respective interventions will result in 1) improved patient safety 2) greater adherence to health care maintenance and chronic disease guidelines 3) more accurate documentation of family history 4) the identification of technology adoption enablers and barriers.


Options:
A: Intervention Type: DEVICE; Name: online health information journal; Assigned to Arm(s): N/A
B: Arm Label: Arm 1; Type: OTHER; Interventions: Behavioral: In Home Health Messaging Device | Intervention Type: BEHAVIORAL; Name: In Home Health Messaging Device; Assigned to Arm(s): Arm 1
C: Intervention Type: BEHAVIORAL; Name: TRANSLATE; Assigned to Arm(s): N/A
D: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Peer counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Assigned a peer counselor | Arm Label: Financial incentives; Type: EXPERIMENTAL; Interventions: Behavioral: Financial incentives | Intervention Type: BEHAVIORAL; Name: Assigned a peer counselor; Assigned to Arm(s): Peer counseling | Intervention Type: BEHAVIORAL; Name: Financial incentives; Assigned to Arm(s): Financial incentives

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Online Health Records for Patient Safety and Care
Brief Summary: The study uses a randomized, prospective cohort design to assess the impact of shared online health records on 1) patient safety, 2) health goal adherence and outcomes, 3) documentation of family history, and 4) barriers to the adoption of patient-physician communication technology.

Hypothesis: the respective interventions will result in 1) improved patient safety 2) greater adherence to health care maintenance and chronic disease guidelines 3) more accurate documentation of family history 4) the identification of technology adoption enablers and barriers.


Options:
A: Arm Label: Integrated Cessation Counseling; Type: EXPERIMENTAL; Interventions: Behavioral: Tobacco Treatment | Arm Label: Usual Care; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Tobacco Treatment | Intervention Type: BEHAVIORAL; Name: Tobacco Treatment; Assigned to Arm(s): Integrated Cessation Counseling, Usual Care
B: Intervention Type: DEVICE; Name: online health information journal; Assigned to Arm(s): N/A
C: Intervention Type: OTHER; Name: educational intervention; Assigned to Arm(s): N/A | Intervention Type: OTHER; Name: internet-based intervention; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: evaluation of cancer risk factors; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: fecal occult blood test; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: screening colonoscopy; Assigned to Arm(s): N/A
D: Arm Label: Mobile application user group; Type: EXPERIMENTAL; Interventions: Behavioral: Daily health-related lifestyle modification prescription | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Daily health-related lifestyle modification prescription; Assigned to Arm(s): Mobile application user group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Online Health Records for Patient Safety and Care
Brief Summary: The study uses a randomized, prospective cohort design to assess the impact of shared online health records on 1) patient safety, 2) health goal adherence and outcomes, 3) documentation of family history, and 4) barriers to the adoption of patient-physician communication technology.

Hypothesis: the respective interventions will result in 1) improved patient safety 2) greater adherence to health care maintenance and chronic disease guidelines 3) more accurate documentation of family history 4) the identification of technology adoption enablers and barriers.


Options:
A: Arm Label: Intervention group 1; Type: EXPERIMENTAL; Interventions: Behavioral: HPV self-sampling kit mailed directly | Arm Label: Intervention group 2; Type: EXPERIMENTAL; Interventions: Behavioral: HPV self-sampling kit on demand | Arm Label: Intervention group 3; Type: EXPERIMENTAL; Interventions: Behavioral: Second reminder | Intervention Type: BEHAVIORAL; Name: HPV self-sampling kit mailed directly; Assigned to Arm(s): Intervention group 1 | Intervention Type: BEHAVIORAL; Name: HPV self-sampling kit on demand; Assigned to Arm(s): Intervention group 2 | Intervention Type: BEHAVIORAL; Name: Second reminder; Assigned to Arm(s): Intervention group 3
B: Intervention Type: DEVICE; Name: online health information journal; Assigned to Arm(s): N/A
C: Arm Label: Stepwise intervention; Type: EXPERIMENTAL; Interventions: Other: Customized text message invitation ( Step 1a), Other: Customized automatic phone call invitation (Step 1b), Other: Secretary phone call (Step 2), Other: Health professional face-to-face appointment (Step 3) | Arm Label: Written Letter; Type: ACTIVE_COMPARATOR; Interventions: Other: Written Letter | Intervention Type: OTHER; Name: Customized text message invitation ( Step 1a); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Customized automatic phone call invitation (Step 1b); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Secretary phone call (Step 2); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Health professional face-to-face appointment (Step 3); Assigned to Arm(s): Stepwise intervention | Intervention Type: OTHER; Name: Written Letter; Assigned to Arm(s): Written Letter
D: Arm Label: control 1; Type: N/A; Interventions: N/A | Arm Label: Intervention 1; Type: N/A; Interventions: N/A | Arm Label: intervention 2; Type: N/A; Interventions: N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supportive Test for Acid-Related Symptoms (STARS I) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Subjects With Upper Gastrointestinal Symptoms and With Normal Findings at Esophagogastroduodenoscopy.
Brief Summary: The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.


Options:
A: Arm Label: colonoscopy; Type: EXPERIMENTAL; Interventions: Device: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test) | Intervention Type: DEVICE; Name: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test); Assigned to Arm(s): colonoscopy
B: Arm Label: Group A - COLO, then TER; Type: EXPERIMENTAL; Interventions: Device: Third Eye Retroscope | Arm Label: Group B - TER, then COLO; Type: ACTIVE_COMPARATOR; Interventions: Device: Third Eye Retroscope | Intervention Type: DEVICE; Name: Third Eye Retroscope; Assigned to Arm(s): Group A - COLO, then TER, Group B - TER, then COLO
C: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
D: Arm Label: Group A (study group); Type: ACTIVE_COMPARATOR; Interventions: Device: Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system | Arm Label: Group B (control group); Type: ACTIVE_COMPARATOR; Interventions: Device: Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system | Intervention Type: DEVICE; Name: Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system; Assigned to Arm(s): Group A (study group), Group B (control group)

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supportive Test for Acid-Related Symptoms (STARS I) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Subjects With Upper Gastrointestinal Symptoms and With Normal Findings at Esophagogastroduodenoscopy.
Brief Summary: The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.


Options:
A: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
B: Arm Label: colonoscopy; Type: EXPERIMENTAL; Interventions: Device: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test) | Intervention Type: DEVICE; Name: Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test); Assigned to Arm(s): colonoscopy
C: Intervention Type: PROCEDURE; Name: Narrow Band Imaging; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Procedure: standard of care colonoscopy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Procedure: standard of care colonoscopy | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Procedure: colonoscopy | Intervention Type: PROCEDURE; Name: standard of care colonoscopy; Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: colonoscopy; Assigned to Arm(s): 3 | Intervention Type: PROCEDURE; Name: standard of care colonoscopy; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised, Double-blind, Parallel-group, Placebo Controlled Study of Esomeprazole i.v. (Bolus Infusion of 80 mg Followed by a Continuous Infusion of 8 mg Per Hour) Administered for 72 Hours to Assess Prevention of Rebleeding in Subjects That Have Undergone Successful Primary Endoscopic Haemostasis of a Bleeding Peptic Ulcer - the PUB Study.
Brief Summary: This study is being carried out to see if constant 3 days infusion of Nexium is effective in preventing rebleeding after an endoscopic treatment.


Options:
A: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A
B: Arm Label: lansoprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: lansoprazole | Arm Label: esomeprazole; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole | Intervention Type: DRUG; Name: lansoprazole; Assigned to Arm(s): lansoprazole | Intervention Type: DRUG; Name: esomeprazole; Assigned to Arm(s): esomeprazole
C: Arm Label: Double oral dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Arm Label: Regular oral dose; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Arm Label: Control group; Type: ACTIVE_COMPARATOR; Interventions: Drug: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) | Intervention Type: DRUG; Name: esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden); Assigned to Arm(s): Control group, Double oral dose, Regular oral dose
D: Intervention Type: DRUG; Name: omeprazole; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: pantoprazole; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Supportive Test for Acid-Related Symptoms (STARS II) With Esomeprazole and a Following 7-week, Double-blind, Randomized, Placebo Controlled Treatment Period in Uninvestigated Subjects With Upper Gastrointestinal Symptoms.
Brief Summary: The aim is to evaluate if the resolution of upper abdominal symptoms (pain or burning) during an acid suppressive test trial of esomprazole given daily for 7 days predicts symptoms resolution at the end of a subsequent treatment period of 7 weeks.


Options:
A: Arm Label: Z-338; Type: EXPERIMENTAL; Interventions: Drug: Z-338 | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Z-338; Assigned to Arm(s): Z-338 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): placebo
B: Intervention Type: DRUG; Name: Itopride (drug); Assigned to Arm(s): N/A
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Cinitapride | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: domperidone | Intervention Type: DRUG; Name: Cinitapride; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: domperidone; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Esomeprazole; Assigned to Arm(s): N/A

Answer: D